Evidence map›Paper›PMID 35721214›Full record

ArticleFrontiers in pharmacology2022

Pyridoxamine and Aminoguanidine Attenuate the Abnormal Aggregation of β-Tubulin and Suppression of Neurite Outgrowth by Glyceraldehyde-Derived Toxic Advanced Glycation End-Products.

Hayahide Ooi, Ryuto Nasu, Ayako Furukawa, Masayoshi Takeuchi, Yoshiki Koriyama

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Review
  3. L-Theanine Extends the Lifespan ofFoods (Basel, Switzerland) · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Identification of Yellow Advanced Glycation End Products in Human Skin.International journal of molecular sciences · 2024
    Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Advanced Glycation End-Products and Diabetic Neuropathy of the Retina.International journal of molecular sciences · 2023
    Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Hayahide OoiGraduate School and Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Japan.
Ryuto NasuGraduate School and Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Japan.
Ayako FurukawaGraduate School and Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Japan.
Masayoshi TakeuchiDepartment of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Uchinada-machi, Japan.
Yoshiki KoriyamaGraduate School and Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Japan.
Suzuka University of Medical Science · JPKanazawa Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus (DM) has been identified as a risk factor for the onset and progression of Alzheimer's disease (AD). In our previous study, we demonstrated that glyceraldehyde (GA)-derived toxic advanced glycation end-products (toxic AGEs, TAGE) induced similar alterations to those observed in AD. GA induced dysfunctional neurite outgrowth

Indexed as

advanced glycation end-productsAlzheimer’sdiabetes mellitusglyceraldehydeβ-tubulin

Identifiers

PMID35721214
PMCPMC9204210
OpenAlexW4281739167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.